Selected research
Industry Research
Drug Safety and Pharmacovigilance (PV) Software Industry Research Report 2026
Market perspective
The global Drug Safety and Pharmacovigilance (PV) Software market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Drug Safety and Pharmacovigilance (PV) Software market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Drug Safety and Pharmacovigilance (PV) Software market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Drug Safety and Pharmacovigilance (PV) Software market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Drug Safety and Pharmacovigilance (PV) Software include Oracle, Veeva Systems, ArisGlobal, IQVIA, EXTEDO, RxLogix, Ennov, Uppsala Monitoring Centre and Medidata, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Drug Safety and Pharmacovigilance (PV) Software market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Drug Safety and Pharmacovigilance (PV) Software.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Drug Safety and Pharmacovigilance (PV) Software Market by Company
Oracle
Veeva Systems
ArisGlobal
IQVIA
EXTEDO
RxLogix
Ennov
Uppsala Monitoring Centre
Medidata
Clarivate
AB Cube
Cloudbyz
Cognizant Technology
Taimei Technology
eMedyun
Bioknow
Singedi Health
Drug Safety and Pharmacovigilance (PV) Software Segment by Type
On-Premises
Cloud-Based
Drug Safety and Pharmacovigilance (PV) Software Segment by Application
Pharma and Biotech Companies
Contract Research Organizations (CROs)
Business Process Outsourcing (BPO) Firms
Other
Drug Safety and Pharmacovigilance (PV) Software Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Safety and Pharmacovigilance (PV) Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drug Safety and Pharmacovigilance (PV) Software and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Safety and Pharmacovigilance (PV) Software.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Drug Safety and Pharmacovigilance (PV) Software companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- On-Premises
- Cloud-Based
Applications
- Pharma and Biotech Companies
- Contract Research Organizations (CROs)
- Business Process Outsourcing (BPO) Firms
- Other
Companies covered
- Oracle
- Veeva Systems
- ArisGlobal
- IQVIA
- EXTEDO
- RxLogix
- Ennov
- Uppsala Monitoring Centre
- Medidata
- Clarivate
- AB Cube
- Cloudbyz
- Cognizant Technology
- Taimei Technology
- eMedyun
- Bioknow
- Singedi Health
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Drug Safety and Pharmacovigilance (PV) Software by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 On-Premises
- 2.2.3 Cloud-Based
- 2.3 Drug Safety and Pharmacovigilance (PV) Software by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharma and Biotech Companies
- 2.3.3 Contract Research Organizations (CROs)
- 2.3.4 Business Process Outsourcing (BPO) Firms
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Drug Safety and Pharmacovigilance (PV) Software Breakdown Data by Type
- 3.1 Global Drug Safety and Pharmacovigilance (PV) Software Historic Market Size by Type (2021-2026)
- 3.2 Global Drug Safety and Pharmacovigilance (PV) Software Forecasted Market Size by Type (2027-2032)
4 Drug Safety and Pharmacovigilance (PV) Software Breakdown Data by Application
- 4.1 Global Drug Safety and Pharmacovigilance (PV) Software Historic Market Size by Application (2021-2026)
- 4.2 Global Drug Safety and Pharmacovigilance (PV) Software Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Drug Safety and Pharmacovigilance (PV) Software Market Perspective (2021-2032)
- 5.2 Global Drug Safety and Pharmacovigilance (PV) Software Growth Trends by Region
- 5.2.1 Global Drug Safety and Pharmacovigilance (PV) Software Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Drug Safety and Pharmacovigilance (PV) Software Historic Market Size by Region (2021-2026)
- 5.2.3 Drug Safety and Pharmacovigilance (PV) Software Forecasted Market Size by Region (2027-2032)
- 5.3 Drug Safety and Pharmacovigilance (PV) Software Market Dynamics
- 5.3.1 Drug Safety and Pharmacovigilance (PV) Software Industry Trends
- 5.3.2 Drug Safety and Pharmacovigilance (PV) Software Market Drivers
- 5.3.3 Drug Safety and Pharmacovigilance (PV) Software Market Challenges
- 5.3.4 Drug Safety and Pharmacovigilance (PV) Software Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Drug Safety and Pharmacovigilance (PV) Software Players by Revenue
- 6.1.1 Global Top Drug Safety and Pharmacovigilance (PV) Software Players by Revenue (2021-2026)
- 6.1.2 Global Drug Safety and Pharmacovigilance (PV) Software Revenue Market Share by Players (2021-2026)
- 6.2 Global Drug Safety and Pharmacovigilance (PV) Software Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Drug Safety and Pharmacovigilance (PV) Software Head Office and Area Served
- 6.4 Global Drug Safety and Pharmacovigilance (PV) Software Players, Product Type & Application
- 6.5 Global Drug Safety and Pharmacovigilance (PV) Software Manufacturers Established Date
- 6.6 Global Drug Safety and Pharmacovigilance (PV) Software Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Drug Safety and Pharmacovigilance (PV) Software Market Size (2021-2032)
- 7.2 North America Drug Safety and Pharmacovigilance (PV) Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Drug Safety and Pharmacovigilance (PV) Software Market Size by Country (2021-2026)
- 7.4 North America Drug Safety and Pharmacovigilance (PV) Software Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Drug Safety and Pharmacovigilance (PV) Software Market Size (2021-2032)
- 8.2 Europe Drug Safety and Pharmacovigilance (PV) Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Drug Safety and Pharmacovigilance (PV) Software Market Size by Country (2021-2026)
- 8.4 Europe Drug Safety and Pharmacovigilance (PV) Software Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Drug Safety and Pharmacovigilance (PV) Software Market Size (2021-2032)
- 9.2 Asia-Pacific Drug Safety and Pharmacovigilance (PV) Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Drug Safety and Pharmacovigilance (PV) Software Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Drug Safety and Pharmacovigilance (PV) Software Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Drug Safety and Pharmacovigilance (PV) Software Market Size (2021-2032)
- 10.2 South America Drug Safety and Pharmacovigilance (PV) Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Drug Safety and Pharmacovigilance (PV) Software Market Size by Country (2021-2026)
- 10.4 South America Drug Safety and Pharmacovigilance (PV) Software Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Drug Safety and Pharmacovigilance (PV) Software Market Size (2021-2032)
- 11.2 Middle East & Africa Drug Safety and Pharmacovigilance (PV) Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Drug Safety and Pharmacovigilance (PV) Software Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Drug Safety and Pharmacovigilance (PV) Software Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Oracle
- 12.1.1 Oracle Company Information
- 12.1.2 Oracle Business Overview
- 12.1.3 Oracle Revenue in Drug Safety and Pharmacovigilance (PV) Software Business (2021-2026)
- 12.1.4 Oracle Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
- 12.1.5 Oracle Recent Developments
- 12.2 Veeva Systems
- 12.2.1 Veeva Systems Company Information
- 12.2.2 Veeva Systems Business Overview
- 12.2.3 Veeva Systems Revenue in Drug Safety and Pharmacovigilance (PV) Software Business (2021-2026)
- 12.2.4 Veeva Systems Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
- 12.2.5 Veeva Systems Recent Developments
- 12.3 ArisGlobal
- 12.3.1 ArisGlobal Company Information
- 12.3.2 ArisGlobal Business Overview
- 12.3.3 ArisGlobal Revenue in Drug Safety and Pharmacovigilance (PV) Software Business (2021-2026)
- 12.3.4 ArisGlobal Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
- 12.3.5 ArisGlobal Recent Developments
- 12.4 IQVIA
- 12.4.1 IQVIA Company Information
- 12.4.2 IQVIA Business Overview
- 12.4.3 IQVIA Revenue in Drug Safety and Pharmacovigilance (PV) Software Business (2021-2026)
- 12.4.4 IQVIA Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
- 12.4.5 IQVIA Recent Developments
- 12.5 EXTEDO
- 12.5.1 EXTEDO Company Information
- 12.5.2 EXTEDO Business Overview
- 12.5.3 EXTEDO Revenue in Drug Safety and Pharmacovigilance (PV) Software Business (2021-2026)
- 12.5.4 EXTEDO Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
- 12.5.5 EXTEDO Recent Developments
- 12.6 RxLogix
- 12.6.1 RxLogix Company Information
- 12.6.2 RxLogix Business Overview
- 12.6.3 RxLogix Revenue in Drug Safety and Pharmacovigilance (PV) Software Business (2021-2026)
- 12.6.4 RxLogix Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
- 12.6.5 RxLogix Recent Developments
- 12.7 Ennov
- 12.7.1 Ennov Company Information
- 12.7.2 Ennov Business Overview
- 12.7.3 Ennov Revenue in Drug Safety and Pharmacovigilance (PV) Software Business (2021-2026)
- 12.7.4 Ennov Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
- 12.7.5 Ennov Recent Developments
- 12.8 Uppsala Monitoring Centre
- 12.8.1 Uppsala Monitoring Centre Company Information
- 12.8.2 Uppsala Monitoring Centre Business Overview
- 12.8.3 Uppsala Monitoring Centre Revenue in Drug Safety and Pharmacovigilance (PV) Software Business (2021-2026)
- 12.8.4 Uppsala Monitoring Centre Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
- 12.8.5 Uppsala Monitoring Centre Recent Developments
- 12.9 Medidata
- 12.9.1 Medidata Company Information
- 12.9.2 Medidata Business Overview
- 12.9.3 Medidata Revenue in Drug Safety and Pharmacovigilance (PV) Software Business (2021-2026)
- 12.9.4 Medidata Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
- 12.9.5 Medidata Recent Developments
- 12.10 Clarivate
- 12.10.1 Clarivate Company Information
- 12.10.2 Clarivate Business Overview
- 12.10.3 Clarivate Revenue in Drug Safety and Pharmacovigilance (PV) Software Business (2021-2026)
- 12.10.4 Clarivate Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
- 12.10.5 Clarivate Recent Developments
- 12.11 AB Cube
- 12.11.1 AB Cube Company Information
- 12.11.2 AB Cube Business Overview
- 12.11.3 AB Cube Revenue in Drug Safety and Pharmacovigilance (PV) Software Business (2021-2026)
- 12.11.4 AB Cube Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
- 12.11.5 AB Cube Recent Developments
- 12.12 Cloudbyz
- 12.12.1 Cloudbyz Company Information
- 12.12.2 Cloudbyz Business Overview
- 12.12.3 Cloudbyz Revenue in Drug Safety and Pharmacovigilance (PV) Software Business (2021-2026)
- 12.12.4 Cloudbyz Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
- 12.12.5 Cloudbyz Recent Developments
- 12.13 Cognizant Technology
- 12.13.1 Cognizant Technology Company Information
- 12.13.2 Cognizant Technology Business Overview
- 12.13.3 Cognizant Technology Revenue in Drug Safety and Pharmacovigilance (PV) Software Business (2021-2026)
- 12.13.4 Cognizant Technology Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
- 12.13.5 Cognizant Technology Recent Developments
- 12.14 Taimei Technology
- 12.14.1 Taimei Technology Company Information
- 12.14.2 Taimei Technology Business Overview
- 12.14.3 Taimei Technology Revenue in Drug Safety and Pharmacovigilance (PV) Software Business (2021-2026)
- 12.14.4 Taimei Technology Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
- 12.14.5 Taimei Technology Recent Developments
- 12.15 eMedyun
- 12.15.1 eMedyun Company Information
- 12.15.2 eMedyun Business Overview
- 12.15.3 eMedyun Revenue in Drug Safety and Pharmacovigilance (PV) Software Business (2021-2026)
- 12.15.4 eMedyun Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
- 12.15.5 eMedyun Recent Developments
- 12.16 Bioknow
- 12.16.1 Bioknow Company Information
- 12.16.2 Bioknow Business Overview
- 12.16.3 Bioknow Revenue in Drug Safety and Pharmacovigilance (PV) Software Business (2021-2026)
- 12.16.4 Bioknow Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
- 12.16.5 Bioknow Recent Developments
- 12.17 Singedi Health
- 12.17.1 Singedi Health Company Information
- 12.17.2 Singedi Health Business Overview
- 12.17.3 Singedi Health Revenue in Drug Safety and Pharmacovigilance (PV) Software Business (2021-2026)
- 12.17.4 Singedi Health Drug Safety and Pharmacovigilance (PV) Software Product Portfolio
- 12.17.5 Singedi Health Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst